SofWave Medical Temettü

Temettü kriter kontrolleri 0/6

SofWave Medical şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.03%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.03%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

We Think Some Shareholders May Hesitate To Increase SofWave Medical Ltd.'s (TLV:SOFW) CEO Compensation

Sep 11

SofWave Medical Ltd. (TLV:SOFW) Screens Well But There Might Be A Catch

May 02

Even With A 27% Surge, Cautious Investors Are Not Rewarding SofWave Medical Ltd.'s (TLV:SOFW) Performance Completely

Jan 31

A Piece Of The Puzzle Missing From SofWave Medical Ltd.'s (TLV:SOFW) 31% Share Price Climb

Nov 17

We're Not Worried About SofWave Medical's (TLV:SOFW) Cash Burn

Nov 13

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

May 05

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

Dec 22

Is SofWave Medical (TLV:SOFW) In A Good Position To Invest In Growth?

Aug 25

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SOFW şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SOFW şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

SofWave Medical Piyasaya Karşı Temettü Getirisi

SOFW temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SOFW)	n/a
Pazarın Alt %25'i (IL)	2.4%
Pazarın En İyi %25'i (IL)	6.4%
Sektör Ortalaması (Medical Equipment)	1.4%
Analist tahmini (SOFW) (3 yıla kadar)	n/a

Önemli Temettü: SOFW şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SOFW şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SOFW şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SOFW herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

SofWave Medical Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

SofWave Medical Ltd. to Report Q3, 2024 Results on Nov 13, 2024

SofWave Medical Ltd. Obtains U.S. Patent for Fat Tissue Reduction Technology

We Think Some Shareholders May Hesitate To Increase SofWave Medical Ltd.'s (TLV:SOFW) CEO Compensation

SofWave Medical Ltd. Appoints Larry Laber to the Role of Executive Vice President, North American Sales

Sofwave Receives FDA Clearance for Pure Impact™ in Strengthening and Firming of Arms in the U.S

Second quarter 2024 earnings released: US$0.045 loss per share (vs US$0.083 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.029 loss per share (vs US$0.11 loss in 1Q 2023)

SofWave Medical Ltd. (TLV:SOFW) Screens Well But There Might Be A Catch

Full year 2023 earnings released: US$0.24 loss per share (vs US$0.57 loss in FY 2022)

SofWave Medical Ltd. Appoints James Bartholomeusz as Chief Innovation Officer

Even With A 27% Surge, Cautious Investors Are Not Rewarding SofWave Medical Ltd.'s (TLV:SOFW) Performance Completely

SofWave Medical Ltd. Receives FDA Clearance of Superb™? Technology for Improvement of the Appearance of Skin Laxity on the Upper Arm

Less than half of directors are independent

SofWave Medical Ltd., Annual General Meeting, Jan 23, 2024

A Piece Of The Puzzle Missing From SofWave Medical Ltd.'s (TLV:SOFW) 31% Share Price Climb

We're Not Worried About SofWave Medical's (TLV:SOFW) Cash Burn

Third quarter 2023 earnings released: US$0.036 loss per share (vs US$0.13 loss in 3Q 2022)

SofWave Medical Ltd. to Report Q3, 2023 Results on Nov 08, 2023

Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Treatment of Acne Scars

Second quarter 2023 earnings released: US$0.083 loss per share (vs US$0.16 loss in 2Q 2022)

New major risk - Share price stability

SofWave Medical Ltd. to Report Q2, 2023 Results on Aug 08, 2023

Sofwave Medical Ltd. Gains Additional U.S. Patent Protection for the Company's Proprietary SUPERB™ Technology

Less than half of directors are independent

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.16 loss in 1Q 2022)

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

Full year 2022 earnings released: US$0.57 loss per share (vs US$0.29 loss in FY 2021)

SofWave Medical Ltd. Gains Market Approval for SUPERB(TM) Non-Invasive Wrinkle Reduction and Lifting Technology in Mexico

Sofwave Medical Ltd Announces Market Approvals for SUPERB(TM) Non-Invasive Wrinkle Reduction Technology Now Extend to Taiwan

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

SofWave Medical Ltd. Announces FDA Clearance of SUPERB™ Technology For Cellulite

SofWave Gains Approval to Market the Superb™ Non-Invasive Wrinkle Reduction Device in Brazil

Sofwave Medical Ltd. Receives Grants U.S. Patent Covering Key Elements of Proprietary Superb™ Non-Surgical Skin and Collagen Remodeling Technology

SofWave Medical Ltd. to Report Q2, 2022 Results on Aug 16, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SofWave Medical Ltd. to Report Q4, 2022 Results on Mar 09, 2022

Chief Financial Officer Michael Eden has left the company

Is SofWave Medical (TLV:SOFW) In A Good Position To Invest In Growth?

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin